AI Terminal
Aladdin Healthcare Technologies SE
Earnings Release • Dec 8, 2020
23_rns_2020-12-08_4521ba72-065a-4c48-9222-f4ca8f309073.html
Earnings Release
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 8 December 2020 12:07
Aladdin Healthcare Technologies SE reports preliminary figures for financial year 2019 and readjustment of the 2018 financial year figures
Aladdin Healthcare Technologies SE / Key word(s): Preliminary Results
Aladdin Healthcare Technologies SE reports preliminary figures for financial year 2019 and readjustment of the 2018 financial year figures
08-Dec-2020 / 12:07 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Aladdin Healthcare Technologies SE reports preliminary figures for financial year 2019 and readjustment of the 2018 financial year figures
Aladdin Healthcare Technologies SE (the “ Company “) reports that in the course of the preparation of its consolidated annual financial statements under IFRS for the financial year 2019, losses in the amount of EUR 2,989.9k will be accounted for due to an EUR 1,532.2k impairment of financial assets. In 2018 there has been a re-adjustment of expenses relating to intellectual property that were originally deemed by the Company as being eligible for capitalisation in the balance sheet. These losses in the amount of EUR 1,430.6k together with losses from operational activities presumably result in total losses for the financial year 2018 in the amount of EUR 5,391.4. The Company is currently in the process of finalising the financial statements for 2019 which are expected to be approved by the Board of Directors and audited by its auditor after the first two weeks of December.
In 2019 the losses from impairment of assets relate to non-current loans, which is in majority made up of a convertible loan to the Hong Kong licensee of the Company. An impairment charge of EUR 1,532.2k will be applied to the loan as management made the decision not to pursue the terms of the license any further and to cease expenditure on any future development with the Shenzhen Guo Yi Hui Hospital Management Co. The loan is not reasonably recoverable at the balance sheet date, therefore an impairment charge for the full outstanding amount has been applied through the profit and loss. The impairment charge in the amount of EUR 1,532.2k together with losses from operational activities will presumably result in total losses for the financial year 2019 of EUR 2,989.9k .
The retained earnings balance before correction was EUR -3,920.4k in the financial year 2018. After correction of losses from the re-adjustment related to the capitalisation of expenses incurred in the financial year 2018 relating to the software of the Company and other smaller adjustments, the retained earnings were reduced by EUR 2.492.7k to a post adjustment balance of EUR -6.413.1k.
Further preliminary key figures of the 2019 consolidated financial statements are as follows:
Balance sheet:
Total assets: EUR 480.5k (2018: EUR 1,919.0k)
Total Equity: EUR -1,765.8k (2018: EUR 1,463.0k)
Total liabilities: EUR 2,246.2k (2018: EUR 456.0k)
Profit and loss:
Revenues: EUR 0 (2018: EUR 174.5k)
Operating loss: EUR 2,989.9k (2018: EUR 5,391.4k)
Contact:
Aladdin Healthcare Technologies SE
Unter den Linden 10
10117 Berlin
Tel 0307700 140 449
email: [email protected]
www.aladdinid.com
08-Dec-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Aladdin Healthcare Technologies SE |
| Unter den Linden 10 | |
| 10117 Berlin | |
| Germany | |
| Phone: | 030 700140449 |
| E-mail: | [email protected] |
| Internet: | www.aladdinid.com |
| ISIN: | DE000A12ULL2 |
| WKN: | A12ULL |
| Listed: | Regulated Market in Dusseldorf |
| EQS News ID: | 1153468 |
| End of Announcement | DGAP News Service |